Professor Kostas Syrigos graduated from Athens School of Medicine in 1988. He was trained in Internal Medicine at the Laikon University Hospital (Athens University) and in Medical Oncology at the Hammersmith Hospital (London University).
He completed his MD thesis with distinction from the Athens School of Medicine in 1995 and his PhD thesis from the Imperial College of Science, Technology and Medicine, London University in 2000. He worked as Senior Registrar in Medical Oncology at the Hammersmith and St Bartholomew’s Hospitals in London and as Consultant at the Sotiria General Hospital in Athens.
In 2002 he was appointed Associate Professor of Oncology in Medicine and Head of the Sotiria Oncology Unit. From 2006 he has also been Visiting Professor of Thoracic Oncology at Yale University, CT, USA. His main fields of interest are targeted therapies, drug development, as well as thoracic and head & neck oncology.
Professor Syrigos has participated in several international phase I–IV clinical trials in lung, colon, head & neck, and pancreatic cancer. His research interests include neoangiogenesis and the role of adhesion molecules in the neovasculature.
He has published several papers on the role of the E-cadherin–catenin pathway in the pathogenesis, prognosis, and prediction of neoplastic diseases. He has also conducted early phase (I–II) clinical trials with agents targeting this pathway.
He is a member of numerous scientific societies. He is a manuscript reviewer for 18 scientific journals and currently serves on the editorial board of 5 scientific journals. He is the editor of 6 International Scientific Volumes, including Tumors of The Chest (2006, Springer). He has contributed 80 chapters in international books and he is the author of 230 peer-reviewed, international articles.